Introduction
CGRP belongs to the calcitonin family of peptides, which also includes adrenomedullin, calcitonin, intermedin (adrenomedullin 2) and amylin. CGRP is widely distributed in sensory nerves throughout the central and peripheral nervous system (Brain et al., 2004) . CGRP is a potent vasodilator, increases blood flow and promotes mast cell degranulation, angiogenesis and endothelial cell proliferation (Brain et al., 1985; Haegerstrand et al., 1990; Ohno et al., 2008; Reynier-Rebuffel et al., 1994) . In contrast, CGRP has anti-proliferative effects in SMCs (Chattergoon et al., 2005; Li et al., 1997) . The relaxing effects of CGRP on the vasculature can be mediated by activating either endothelial cells or smooth muscle cells. For example, CGRP relaxes human radial, coronary, gastric and cerebral arteries via an endothelium-dependent pathway (Thom et al., 1987) . Whereas CGRP acts solely on smooth muscle cells receptors in human and porcine coronary arteries (Shoji et al., 1987) . In addition to vasodilatation CGRP has been shown to be beneficial in protecting against myocardial ischaemia (Wu et al., 2001 ) and heart and kidney damage caused by hypertension (Supowit et al., 2005) .
Noxious stimuli and trauma can lead to release of CGRP and another neuropeptide, substance P from primary sensory neurons. Centrally, release of CGRP and substance P facilitates nociceptive transmission and in the periphery they mediate neurogenic inflammation, which is characterized by neutrophil infiltration, oedema and vasodilatation (McDonald, 1988) . These processes are important characteristics of many human diseases including asthma, arthritis, and inflammatory bowel diseases.
CGRP has been implicated in the pathogenesis of migraine as infusion of CGRP caused delayed headaches in patients suffering from primary headache diseases 
Animals
Male Wistar rats (200-300 g) were killed by cervical dislocation following institutional guidelines for animal welfare and schedule 1 of the Animals (scientific procedures) Act 1986. The mesenteric vascular bed was excised and immediately placed in ice cold Krebs solution containing (mM): NaCl, 118.0; NaCO 3 , 24; KCl, 3.6; KH 2 PO 4 , 1.2; MgSO 4 ⋅7H 2 O, 1.2; glucose, 11.0; CaCl 2 , 2.5.
Primary Cell Culture
RMA-SMCs were obtained using an explant method. Briefly, the mesenteric vascular tree was pinned out and mesenteric arteries (3 rd order) were cut longitudinally and pieces (1 mm) placed in DMEM containing 10% heat-inactivated foetal bovine serum, 1% non-essential amino acids, penicillin-streptomycin and fungizone. After 7-10 days, migrated cells were pooled and maintained in medium (as above). Cells were used for experiments between passages 2-4. All cells were routinely grown in 95% air, 5% CO 2 at 37°C.
Immunofluorescence
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RMA-SMCs were washed in 100 mM PBS, pH 7.4, and fixed in PBS containing 4% paraformaldehyde, pH 7.4 (20 min, 4°C) or in methanol (100%, -20ºC, 10 min). Cells were washed with PBS containing 0.1% saponin and 2% normal horse serum (30 min, room temperature). Proteins were localized using the primary antibodies: ECE-1
(1:200), α-smooth muscle actin (1:200) and EEA1 (1:500) (overnight, 4°C). Cells were washed, incubated with appropriate secondary antibodies (1:500, 2 h, room temperature) and mounted in Vectashield (Vector Laboratories Ltd., Peterborough, UK).
To obtain whole mount preparations, arteries were prepared using a perfusion fix protocol; the mesenteric vascular bed was excised and perfused with Krebs solution for 5 min as previously described (McNeish et al., 2002) . Arteries were then perfusion fixed for 10 min with 100 mM PBS, pH 7.4 containing 1% paraformaldehyde, 10 µM sodium azide and 10 mM betaine. Arteries (3 rd order) were excised, cut longitudinally and pinned flat on sylgard plates and fixed (100 mM PBS, pH 7.4, 4% paraformaldehyde, 2 h, 4ºC). Artery whole mounts were washed in PBS containing 10% normal horse serum and 0.3% Triton-X-100 (1 h, room temperature) and proteins localized using the primary antibodies: ECE-1 (1:200) and PECAM-1
(1:200) (48 h, 4ºC). Whole mounts were washed (1 h, room temperature), incubated with appropriate secondary antibodies (1:500, 2 h, room temperature) and mounted in ProLong ® Gold (Invitrogen, Paisley, UK). To obtain sections, rat mesenteric arteries (3 rd order) were embedded in OCT and sectioned at 10 µm and fixed in 100 mM PBS, pH 7.4 containing 4% paraformaldehyde (30 min, 4ºC). Sections were washed in PBS containing 10% normal horse serum and 0.3% Triton-X-100 (1 h, room temperature) and proteins localized using the primary antibodies: ECE-1 
Confocal Microscopy
For epifluorescence microscopy, cells were observed using a Leica DMI4000B microscope using NPlanL20X/0.35 objective with a Leica DFC420C camera. For confocal microscopy, cells, whole mounts and sections were observed with a Zeiss laser-scanning confocal microscope (LSM Meta 510) using EC Plan-Neofluar 20x/0.5, EC Plan-Neofluar 40x/1.3 Oil DIC and Plan-Apochromat 63x/1.4 Oil DIC objectives. Images were collected at a zoom of 1-2 and an iris of <3 µm, and at least five optical sections were taken at intervals of 0.5 µm. Single sections are shown.
Images were processed using ImageJ and Adobe Photoshop software. to ensure that responses to CGRP were maintained in the absence of SM-19712.
Isolated artery tension recording
Drug Treatments
Confluent wells (12-well plates) of RMA-SMCs were used for experimentation. To 
SDS-PAGE and Western Blotting
Cell lysates (10 µg) were prepared as described (Cottrell et al., 2009) . Proteins were separated by SDS-PAGE (12% acrylamide) and transferred to polyvinylidene fluoride membranes. Membranes were incubated with antibodies to pERK1/2 (1:1000) and ERK2 (1:10,000) overnight at 4°C. Membranes were treated with secondary antibodies coupled to horseradish peroxidase (1:10,000) and immunoreactive proteins visualized by enhanced chemiluminescence and quantified using an ImageQuant RT ECL machine (GE Healthcare, Little Chalfont, UK) with ImageQuantTL software.
Reverse Transcription-PCR
RNA from intact rat mesenteric arteries (3 rd order) and RMA-SMCs was isolated using Trizol (Invitrogen) and was reverse-transcribed using standard protocols with random hexamers and TaqMan reverse transcription reagents (Applied Biosystems, Carlsbad, CA, USA). Subsequent PCR reactions used primers specific for rat CLR, RAMP1 and ECE-1 isoforms (Supplementary Table 1 ). Control reactions omitted reverse transcriptase. PCR products were separated by electrophoresis, stained with ethidium bromide, and sequenced to confirm identity.
Antibody Preadsorption
Membranes were prepared from HEK cells transfected with CLR•RAMP1, ECE-1c-GFP or empty vector (control), were prepared as described (Cottrell et al., 2009 et al., 2011) .
Results
CGRP causes vasodilatation of rat mesenteric arteries via an endotheliumindependent mechanism. CGRP is a potent vasodilatory peptide in rat mesenteric resistance arteries (Kawasaki et al., 1988) . In order to examine if ECE-1 regulates CGRP-induced relaxation of rat mesenteric arteries, we first determined the site of action of CGRP. We hypothesized that CGRP would act on SMCs directly and relaxation would occur via an endothelium-independent mechanism. In vehicle- RMA-SMCs express mRNA for CLR, RAMP1 and ECE-1 isoforms and ECE-1 is localized to early endosomes in RMA-SMCs. To assess if ECE-1 is appropriately localized to regulate CLR•RAMP1, we first characterized cultured RMA-SMCs. Our cultured cells were all positive for the SMC marker, α-smooth muscle actin ( Figure   1A ). Next, we examined expression of CLR, RAMP1 and all four ECE-1 isoforms in RMA-SMCs by RT-PCR. We amplified mRNA of expected sizes for CLR, RAMP1
and each of ECE-1 isoforms and confirmed identity by sequencing ( Figure 1B CLR, RAMP1 and ECE-1 are localized to the smooth muscle layer of rat mesenteric arteries. We examined expression of CLR, RAMP1 and all four ECE-1 isoforms in intact rat primary mesenteric arteries by RT-PCR. We amplified mRNA of expected sizes for CLR, RAMP1 and each of ECE-1 isoforms and confirmed identity by sequencing ( Figure 3A) . Examination of ECE-1 expression at the protein level was determined by staining whole mounts of rat mesenteric arteries.
Immunoreactive ECE-1 was detected in the PECAM-1-positive (endothelial) layer and PECAM-1-negative (smooth muscle) layers of arteries ( Figure 3B ). We also Figure 4C , Table 1 ).
Discussion and Conclusions
In this study, we demonstrate for the first time that ECE-1 regulates the resensitization of CGRP responses in SMCs and regulates CGRP-induced relaxation of mesenteric resistance arteries. CLR and RAMP1 are only coexpressed in the smooth muscle layer of mesenteric arteries, a finding that mimics the expression pattern observed in cranial arteries (Lennerz et al., 2008) . Therefore, we used et al., 1999; Granchi et al., 2002; Jackson et al., 2006) . In human umbilical artery SMCs, ECE-1 was present in punctate perinuclear vesicles, similar to the early endosomal vesicles observed in our experiments (Barnes et al., 1999) . ECE-1 protein has also been detected in human temporal arteries (Lozano et al., 2010) , although the location of ECE-1 in these vessels remains undetermined. Thus, we are the first to show the endosomal location of ECE-1 in SMCs, where it may degrade internalized CGRP and perhaps other neuropeptides, to regulate GPCR recycling and resensitization.
Our experiments indicated that RMA-SMCs express a functional CGRP receptor.
CGRP induced a concentration-dependent increase in levels of cAMP and phosphorylation of ERK1 and ERK2. In support of this observation, CGRP has been
shown to induce accumulation of cAMP and/or phosphorylation of ERKs in many cell types, including smooth muscle, endothelial and epithelial cells (Hirata et al., 1988; Kawase et al., 1999; Kubota et al., 1985; Van Valen et al., 1990; Yu et al., 2006) . One interpretation of our cAMP data is CGRP gives a typical biphasic curve, with the first increase (CGRP, 0.1-10 nM) reflecting activation of CLR•RAMP1. The latter increase (CGRP, 1 µM) probably reflecting the ability of CGRP to activate adrenomedullin receptors at high concentrations (Roh et al., 2004) . However, further experimentation would be required to confirm the biphasic nature of the CGRP response in RMA-SMCs. This biphasic phenomenon of the CGRP response was not observed in our artery relaxation studies as 100% relaxation was achieved before using micromolar concentrations of CGRP.
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SM-19712 is a highly selective and potent inhibitor of ECE-1 that prevents the conversion of big endothelin-1 to endothelin-1 by solubilized rat lung microsomes (IC 50 , 42 nM) and by cultured porcine aortic endothelial cells (IC 50 , 31 µM).
However, unlike other ECE-1 inhibitors such as phosphoramidon, which can inhibit metallopeptidases such as neprilysin (neutral endopeptidase 24.11) and angiotensin Iconverting enzyme (Kukkola et al., 1995) that may play a role in the metabolism of CGRP (Kramer et al., 2006; Tramontana et al., 1991) , SM-19712 (10-100 µM) has no effect on these peptidases (Umekawa et al., 2000) . et al., 1998; Padilla et al., 2007) . Conversely, ECE-1 overexpression promoted resensitization of CGRP-induced Ca 2+ -signaling .
Our results strongly suggest CGRP-induced relaxation is solely dependent on activation of CGRP receptors on SMCs, as inhibitors of nitric oxide generation (L-NAME), prostaglandin production (indomethacin), and the endothelium-derived hyperpolarizing factor response (block of SK Ca (apamin) and IK Ca channels (TRAM34)) had no effect on CGRP-induced relaxation of these arteries. This finding is in agreement with a previous study showing that CGRP induces relaxation of rat et al., 1994) and supported by the colocalization of CLR and RAMP1 only in the smooth muscle layer of mesenteric arteries (Cottrell et al., 2005) .
Interestingly, in rat dura mater and human cranial vessels CLR and RAMP1 have also been localized to the smooth muscle layers (Edvinsson et al., 2010; Oliver et al., 2002) , suggesting that CGRP may regulate brain blood flow via a similar mechanism to the one existing in the mesentery. Thus, the mesenteric artery may represent a useful model to study CGRP receptor regulation in relation to brain disorders.
We further characterized the role of ECE-1 in regulation of CGRP responses by examining the effects of SM-19712 on CGRP-induced relaxation of isolated rat mesenteric arteries. ECE-1 inhibition had no effect on the pEC 50 for initial challenges with CGRP, which is unsurprising, as ECE-1 does not affect [Ca 2+ ] i mobilization to initial challenges of CGRP . However, the potency of CGRP (5 min later) was reduced in vehicle-and SM-19712-treated arteries, indicating CGRP receptor desensitization. Similarly, tachyphylaxis to CGRP has been observed in other studies using rat mesenteric arteries (Han et al., 1990) and rat intramural coronary arteries (Sheykhzade et al., 2004) . Although, the pEC 50 following SM-19712-treatment reflects a greater degree of desensitization, we hypothesize that this difference in potency is due to rapid recycling of CGRP receptors in the control group and not a greater desensitization/activation of CGRP receptors following SM-19712-treatment. Indeed, at 30 min in arteries treated with vehicle, the pEC 50 for CGRPinduced relaxation had returned to initial values, indicating CGRP receptor resensitization. In contrast, ECE-1 inhibition prevented CGRP receptor resensitization at 30 min. The kinetics of resensitization we observed in arteries, were much faster than those observed in HEK-CLR RAMP1 cells . However, Furthermore, it may also reflect differences in levels of ECE-1 expression. Previous studies have shown that ECE-1 knockdown or overexpression can alter the kinetics of resensitization of ECE-1-regulated GPCRs . If this ECE-1-dependent mechanism operates in the cerebral sites implicated in migraine remains to be determined. However, as CLR and RAMP1 are expressed in the smooth muscle, but not endothelial layer of the cerebral vasculature (Oliver et al., 2002) it would seem likely, provided that ECE-1 is also expressed in this location. The degranulation of mast cells, which leads to the release of histamine, has also been suggested to play an important role in the pathophysiology of migraine (Levy, 2009; Sicuteri, 1963) . It is well established that CGRP can trigger mast cell degranulation (Piotrowski et al., 1986) , but whether ECE-1 regulates the recycling and resensitization of CGRP receptors in mast cells has yet to be determined. However, if these cells do express ECE-1 it is likely that mast cell CGRP receptors would also be regulated by the same mechanism.
It has been postulated that certain migraineurs may be sensitized to the effects of CGRP, by the upregulation of RAMP1 (Zhang et al., 2007) . Indeed, mice overexpressing human RAMP1 demonstrate an increased sensitivity to CGRP and exhibit light-aversive behavior similar to photophobia in migraine patients (Recober et al., 2009 21 not yet known, but it is an enticing possibility. In support of this notion, it has been reported that many migraineurs have elevated levels of endothelin-1 (a vasoactive peptide generated by the proteolytic activity of ECE-1) (Farkkila et al., 1992) . This lead to the hypothesis that antagonism of endothelin A receptors would be an effective treatment for migraine. However, although bosentan, a selective endothelin A receptor antagonist was effective at reducing neurogenic plasma extravasation in rats, it was ineffective as a treatment in humans for migraine (May et al., 1996) .
The mechanism by which ECE-1 promotes recycling of GPCRs from endosomes back to the cell-surface to mediate resensitization of signalling appears to be common for receptors with peptide ligands that are substrates for ECE-1 only at endosomal pH and that exhibit a sustained interaction with β-arrestins Roosterman et al., 2008) . In the acidified environment of endosomes, ECE-1 degrades the peptide ligands to inactive metabolites disrupting the peptidereceptor-β-arrestin complex, allowing the receptor to recycle to the cell-surface.
However, it remains to be determined whether this mechanism also controls CGRPinduced endosomal-based signalling, as it does for substance P-induced ERK activation from the neurokinin-1 receptor (Cottrell et al., 2009 ).
In conclusion, we report that vascular ECE-1 activity promotes the resensitization of 
